D-NAME

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H140101

CAS#: 141968-19-6

Description: An enantiomer of L-NAME, D-NAME is a weak nitric oxide synthetase inhibitor.

Chemical Structure

img
D-NAME
CAS# 141968-19-6
Instruction

Theoretical Analysis

Hodoodo Cat#: H140101
Name: D-NAME
CAS#: 141968-19-6
Chemical Formula: C8H16N4O4
Exact Mass: 232.12
Molecular Weight: 232.240
Elemental Analysis: C, 41.37; H, 6.94; N, 24.13; O, 27.56

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 51298-62-5  

Synonym: L-NAME

IUPAC/Chemical Name: methyl (R,E)-2-amino-5-((amino(carboxyamino)methylene)amino)pentanoate

InChi Key: WSXMVRLABAVBQK-RXMQYKEDSA-N

InChi Code: InChI=1S/C8H16N4O4/c1-16-6(13)5(9)3-2-4-11-7(10)12-8(14)15/h5H,2-4,9H2,1H3,(H,14,15)(H3,10,11,12)/t5-/m1/s1

SMILES Code: COC([C@H](N([H])[H])CCC/N=C(N(C(O)=O)[H])\N([H])[H])=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 232.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Babál P, Pechánová O, Bernátová I. Long-term administration of D-NAME induces hemodynamic and structural changes in the cardiovascular system. Physiol Res. 2000;49(1):47-54. PMID: 10805404.


2: Liu T, Zhang M, Mukosera GT, Borchardt D, Li Q, Tipple TE, Ishtiaq Ahmed AS, Power GG, Blood AB. L-NAME releases nitric oxide and potentiates subsequent nitroglycerin-mediated vasodilation. Redox Biol. 2019 Sep;26:101238. doi: 10.1016/j.redox.2019.101238. Epub 2019 Jun 4. PMID: 31200239; PMCID: PMC6565607.


3: Halkar RK, Aarsvold JN. Intraoperative probes. J Nucl Med Technol. 1999 Sep;27(3):188-93; quiz 195-6. PMID: 10512473.


4: Pechánová O, Bernátová I, Babál P. Structural alterations in the heart after long-term L-NAME and D-NAME treatment. Gen Physiol Biophys. 1999 Dec;18 Suppl 1:6-9. PMID: 10707823.


5: Duarte ID, Ferreira SH. L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway. Mediators Inflamm. 2000;9(1):25-30. doi: 10.1080/09629350050024348. PMID: 10877451; PMCID: PMC1781740.


6: Das R, Kravtsov GM, Ballard HJ, Kwan CY. L-NAME inhibits Mg(2+)-induced rat aortic relaxation in the absence of endothelium. Br J Pharmacol. 1999 Sep;128(2):493-9. doi: 10.1038/sj.bjp.0702737. PMID: 10510463; PMCID: PMC1571625.


7: Káldi I, Dittmar M, Pierce P, Anderson RE. L-NAME protects against acute light damage in albino rats, but not against retinal degeneration in P23H and S334ter transgenic rats. Exp Eye Res. 2003 Apr;76(4):453-61. doi: 10.1016/s0014-4835(02)00334-2. PMID: 12634110.


8: Cui S, Shibamoto T, Liu W, Takano H, Zhao ZS, Kurata Y. Effects of Hct on L-NAME-induced potentiation of anaphylactic presinusoidal constriction in perfused rat livers. J Cardiovasc Pharmacol. 2006 Jul;48(1):827-33. doi: 10.1097/01.fjc.0000232063.87708.29. PMID: 16891911.


9: Seckler JM, Grossfield A, May WJ, Getsy PM, Lewis SJ. Nitrosyl factors play a vital role in the ventilatory depressant effects of fentanyl in unanesthetized rats. Biomed Pharmacother. 2022 Feb;146:112571. doi: 10.1016/j.biopha.2021.112571. Epub 2021 Dec 22. PMID: 34953397; PMCID: PMC8776621.


10: Shibamoto T, Ruan Z, Cui S, Liu W, Zhao ZS, Takano H, Kurata Y, Koizumi T, Kubo K. The sinusoidal pressure during ischemia-reperfusion injury in perfused mouse liver pretreated with or without L-NAME. J Surg Res. 2007 May 1;139(1):30-5. doi: 10.1016/j.jss.2006.07.052. Epub 2007 Feb 9. PMID: 17292416.


11: Wayman CP, Pike NV, Wilson JF. N-methyl-D-aspartate (NMDA) stimulates release of alpha-MSH from the rat hypothalamus through release of nitric oxide. Brain Res. 1994 Dec 15;666(2):201-6. doi: 10.1016/0006-8993(94)90773-0. PMID: 7882030.


12: Turner CH, Takano Y, Owan I, Murrell GA. Nitric oxide inhibitor L-NAME suppresses mechanically induced bone formation in rats. Am J Physiol. 1996 Apr;270(4 Pt 1):E634-9. doi: 10.1152/ajpendo.1996.270.4.E634. PMID: 8928770.


13: Rehman A, Whiteman M, Halliwell B. Scavenging of hydroxyl radicals but not of peroxynitrite by inhibitors and substrates of nitric oxide synthases. Br J Pharmacol. 1997 Dec;122(8):1702-6. doi: 10.1038/sj.bjp.0701556. PMID: 9422817; PMCID: PMC1565113.


14: Shimada K, Uzui H, Ueda T, Lee JD, Kishimoto C. N-Acetylcysteine Ameliorates Experimental Autoimmune Myocarditis in Rats via Nitric Oxide. J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):203-10. doi: 10.1177/1074248414547574. Epub 2014 Aug 20. PMID: 25147347.


15: Sugimoto Y, Yamada J, Yoshikawa T, Horisaka K. Inhibitory effects of a nitric oxide synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), on 2-deoxy-D-glucose-induced hyperglycemia in rats. Biol Pharm Bull. 1997 Dec;20(12):1307-9. doi: 10.1248/bpb.20.1307. PMID: 9448110.


16: Teixeira MM, Williams TJ, Hellewell PG. Role of prostaglandins and nitric oxide in acute inflammatory reactions in guinea-pig skin. Br J Pharmacol. 1993 Dec;110(4):1515-21. doi: 10.1111/j.1476-5381.1993.tb13994.x. PMID: 8306095; PMCID: PMC2175893.


17: Moreno Júnior H, Nathan LP, Metze K, Costa SK, Antunes E, Hyslop S, Zatz R, de Nucci G. Non-specific inhibitors of nitric oxide synthase cause myocardial necrosis in the rat. Clin Exp Pharmacol Physiol. 1997 May;24(5):349-52. doi: 10.1111/j.1440-1681.1997.tb01200.x. PMID: 9143786.


18: Souza HC, Ballejo G, Salgado MC, Da Silva VJ, Salgado HC. Cardiac sympathetic overactivity and decreased baroreflex sensitivity in L-NAME hypertensive rats. Am J Physiol Heart Circ Physiol. 2001 Feb;280(2):H844-50. doi: 10.1152/ajpheart.2001.280.2.H844. PMID: 11158985.


19: Hogaboam CM, Collins SM, Blennerhassett MG. Effects of oral L-NAME during Trichinella spiralis infection in rats. Am J Physiol. 1996 Aug;271(2 Pt 1):G338-46. doi: 10.1152/ajpgi.1996.271.2.G338. PMID: 8770050.


20: Tsai WC, Strieter RM, Zisman DA, Wilkowski JM, Bucknell KA, Chen GH, Standiford TJ. Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae. Infect Immun. 1997 May;65(5):1870-5. doi: 10.1128/iai.65.5.1870-1875.1997. PMID: 9125574; PMCID: PMC175233.